Quick Takeaways
- UBS Group AG filed SCHEDULE 13G for REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock, par value $0.0001 per share (RVPH).
- Disclosed ownership: 5.8%.
- Date of event: 31 Mar 2026.
UBS Group AG - 31 Mar 2026 SCHEDULE 13G Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock, par value $0.0001 per share (RVPH)
- Filing Manager
- UBS Group AG
- Reporting Manager
- UBS Group AG
- Symbol
- RVPH
- Shares outstanding
- 12,863,707 shares
- Disclosed Ownership
- 746,095 shares
- Ownership
- 5.8%
- Form type
- SCHEDULE 13G
- Filing time
- 07 May 2026, 12:56:18 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"UBS Group AG disclosed 5.8% ownership in REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock, par value $0.0001 per share (RVPH) on 31 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 May 2026, 12:56.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| UBS Group AG | 5.8% | 746,095 | 0 | 746,095 | Andrew Johnson | Director |